OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

XLH is characterized by excess FGF23, hypophosphatemia, skeletal deformities, and growth impairment. For the last 40 years, XLH has been treated with multiple daily doses of oral phosphate and active vitamin D (Pi/D). Burosumab, a fully human monoclonal antibody to FGF23, has been approved by the FD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Imel, Erik, Whyte, Michael, Munns, Craig, Portale, Anthony, Ward, Leanne, Nilsson, Ola, Simmons, Jill, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, San Martin, Javier, Glorieux, Francis
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Bone and Mineral Metabolism
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555067/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR13-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados